Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty

Could Halozyme Therapeutics be the next big opportunity in biotech? Join our experts as they dissect the companys strengths and weaknesses, revealing what investors need to know.

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com

Halozyme Therapeutics completes $1.5 billion convertible notes offering

Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme (HALO) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEMonday, Nov. 3, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Helen TorleySenior Vice President and Chief Financial Officer — Nicole LaBrosseNeed a quote from a Motley Fool analyst? Email [email protected] Revenue -- Total revenue was $354 million in Q3 2025, up 22% year over year, reflecting contributions from royalty revenue and product sales.Royalty Revenue -- Royalty revenue totaled $236 million in Q3 2025, increas...

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Heres Why Halozyme Therapeutics (HALO) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Halozyme Therapeutics, Inc. (HALO) Discusses To Acquire Elektrofi Conference Call (Transcript)

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day

Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.

Halozyme Therapeutics Aktie: Mega-Katalysator durch FDA-Zulassung - Kursziel auf 85 Dollar erhöht

New York (www.aktiencheck.de) - Halozyme Therapeutics-Aktienanalyse von H.C. Wainwright & Co.:Die Analysten von H.C. Wainwright haben das Kursziel für die Aktie von Halozyme Therapeutics Inc. (ISIN: US40637H1095, WKN: A0DLHS, Ticker-Symbol: RV7, NASDAQ-Symbol: HALO) von 75 auf 85 US-Dollar erhöht und ihre "buy"-Empfehlung bekräftigt. [mehr]

Bull of the Day: Halozyme Therapeutics (HALO)

The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth

Halozyme Therapeutics stock hits all-time high at 77.6 USD By Investing.com

Halozyme Therapeutics stock hits all-time high at 77.6 USD

Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Lets find out.

Halozyme Therapeutics - ENHANZE-Lizenzeinnahmen schieben Ergebnis deutlich an!

Geschäftstreiber: Der US-Biotechkonzern Halozyme Therapeutics (HALO) hat sich auf Produkte im Bereich proprietäre Enzymtechnologie spezialisiert. Die von Halozyme entwickelte ENHANZE-Technologie ermöglicht...

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Heres Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.